NCT04015700View on ClinicalTrials.gov

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

May 13, 2022

Study Completion Date

December 31, 2025

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics

-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.

DEVICE

CELLECTRA®2000 EP Device supplied by Geneos Therapeutics

CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

DRUG

Plasmid encoded IL-12

The INO-9012 vials will be supplied by Geneos Therapeutics

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Geneos Therapeutics
All Listed Sponsors
collaborator

Geneos Therapeutics

INDUSTRY

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER